News articles about Viking Therapeutics (NASDAQ:VKTX) have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Viking Therapeutics earned a news impact score of 0.18 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 48.0411331620836 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media stories that may have effected Accern Sentiment’s analysis:
- VKTX May 2018 2.500 call (finance.yahoo.com)
- Viking Therapeutics (VKTX) Upgraded to Strong-Buy at ValuEngine (americanbankingnews.com)
- FY2018 Earnings Estimate for Viking Therapeutics Issued By Zacks Investment Research (VKTX) (americanbankingnews.com)
- VKTX: Enrollment of Phase 2 Trial of VK2809 Nearing Completion (finance.yahoo.com)
- Viking Therapeutics (VKTX) Expected to Post Earnings of -$0.11 Per Share (americanbankingnews.com)
A number of analysts recently issued reports on the company. Maxim Group restated a “buy” rating and issued a $8.00 price target on shares of Viking Therapeutics in a research report on Thursday, March 8th. ValuEngine upgraded Viking Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. BidaskClub upgraded Viking Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 7th. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Viking Therapeutics in a research report on Monday, March 26th. Finally, Roth Capital set a $8.00 target price on Viking Therapeutics and gave the stock a “buy” rating in a research note on Thursday, March 8th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Viking Therapeutics has a consensus rating of “Buy” and a consensus price target of $9.00.
Viking Therapeutics (NASDAQ:VKTX) last released its earnings results on Wednesday, May 9th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. equities research analysts forecast that Viking Therapeutics will post -0.45 earnings per share for the current fiscal year.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.